Nateglinide therapy for type 2 diabetes mellitus (Q34449447)

2 August 2017

1 reference

title

Nateglinide therapy for type 2 diabetes mellitus (English)

1 reference

2 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

T L Levien

1

1 reference

2 August 2017

D E Baker

series ordinal

2

1 reference

2 August 2017

R K Campbell

series ordinal

3

1 reference

2 August 2017

J R White

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Annals of Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

35

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1426-1434

1 reference

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

2 August 2017

cites work

1 reference

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

21 January 2018

1 reference

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

21 January 2018

1 reference

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.

21 January 2018

1 reference

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

21 January 2018

1 reference

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

Postprandial blood glucose. American Diabetes Association

21 January 2018

1 reference

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study

21 January 2018

1 reference

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1A061

1 reference

release_uz6npcl2xncx5hukqnkcl6y2du

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uz6npcl2xncx5hukqnkcl6y2du

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference